Monlunabant
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
Inversago Pharma · Phase 2 · Completed · Enrollment 243
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Low dose | n/r | n/r | n/r | n/r | n/r |
| High dose | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
| Middle Dose | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.